ZBED3: A Potential Drug Target and Biomarker (G84327)

Target Name: ZBED3

NCBI ID: G84327

ZBED3

ZBED3: A Potential Drug Target and Biomarker

Introduction

Zinc-binding protein (ZBP) is a family of transmembrane proteins that play a crucial role in various cellular processes, including cell signaling, DNA replication, and stress responses. One of the ZBP families, ZBED3 (Zinc-Binding E3 domain), has has been identified as a potential drug target and biomarker. In this article, we will discuss the structure and function of ZBED3, its potential implications as a drug target, and its potential as a biomarker for various diseases.

Structure and Function

ZBED3 is a 25kDa protein that consists of an N-terminal ZBP domain, a unique N-terminal region, a transmembrane region, and a C-terminal region. The ZBP domain is a key region that binds zinc ions, while the unique N- The terminal region contains a putative N-acyl transferase (NAT) domain and a calcimulin-like domain. The transmembrane region contains four putative transmembrane domains, including an N-terminal region, a middle region, and two C-terminal regions.

ZBED3 functions as a negative regulator of the transcription factor, p53. It interacts with p53 and prevents it from activating target genes. This interaction between ZBED3 and p53 explains the unique role of ZBED3 in cell signaling. ZBED3 can also act as a negative regulator of the DNA replication machinery, preventing the initiation of DNA replication in response to stress or growth factors.

Potential Drug Target

The potential drug target of ZBED3 is its interaction with p53. Activation of p53 by ZBED3 can lead to the inhibition of its transcriptional activity, leading to the silencing of target genes. This interaction between ZBED3 and p53 makes it an attractive target for small molecules that can inhibit the activity of p53. Currently, several inhibitors have been shown to interact with ZBED3 and prevent its interaction with p53. These inhibitors have the potential to be used as anti-cancer agents.

Potential Biomarkers

ZBED3 can also be used as a biomarker for various diseases. One of the most promising applications of ZBED3 is its potential as a biomarker for cancer. ZBED3 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer . By using ZBED3 as a biomarker, researchers can monitor the effectiveness of cancer treatments and track disease progression.

In addition to its potential as a cancer biomarker, ZBED3 has also been shown to be involved in other cellular processes. For example, ZBED3 has been shown to play a role in cell signaling, DNA replication, and stress responses. Its role in these processes makes it an attractive candidate for biomarkers that can be used to monitor disease progression and therapeutic responses.

Conclusion

In conclusion, ZBED3 is a unique protein that has the potential to be a drug target and biomarker. Its interaction with p53 and its role in cell signaling, DNA replication, and stress responses make it an attractive target for small molecules that can inhibit its activity . Its potential as a cancer biomarker also makes it an attractive candidate for the development of new cancer therapies. Further research is needed to fully understand the role of ZBED3 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Zinc Finger BED-type Containing 3

Functions: Acts as a positive regulator in the activation of the canonical Wnt/beta-catenin signaling pathway by stabilizing cytoplasmic beta-catenin (By similarity). Involved in transcription activation of Wnt target gene expression (By similarity). Plays a role in symmetric division of blastomeres in the early stages of embryogenesis via regulation of mitotic spindle central positioning and organization of the F-actin filament network (By similarity). Plays a role in regulating the distribution of cellular organelles, via modulation of cytoskeletal dynamics and cytoplasmic lattice formation (By similarity)

The "ZBED3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZBED3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets